Two breast PDO studies pair antibody/nanobody distribution with ADC-associated morphology and viability to guide imaging, dose design and efficacy comparisons.
STUDY EVIDENCE
Breast cancer PDO studies combine frozen-section distribution of labeled antibody/nanobody formats with post-ADC morphology and dose response to inform molecular format, imaging conditions and candidate evaluation.
Bright-field, DAPI, AF549 and merged views show the relative distribution of labeled molecules in PDO sections.
Guides refinement of molecular format, timing and imaging endpoints
Bright-field views under control, 0.3 μM and 3.0 μM conditions provide morphological context for viability readouts.
Pairs morphological change with quantitative viability readouts
The curves show different viability profiles across a candidate ADC concentration range in two PDO models, with replication and statistical analysis supporting dose-window selection and follow-on candidate comparison.
Compares model-level response differences and informs follow-on sample studiesINTERPRETATION
Plan ADC imaging, dose selection and candidate comparisons using labeled-antibody/nanobody distribution and ADC activity readouts.
For a new ADC program, spatial imaging and activity testing can be combined in one study to connect target expression, tissue distribution and response.
Evaluate target profiling, competition controls and time-course imaging alongside apoptosis and independent-sample results.
Related models and services
PROJECT DISCUSSION
Share the target, molecular format, tumor model and the distribution, dose-response or killing endpoints you want to compare.
